Loading

Journal of Hematology and Transfusion

First-In-Human HighCumulative-Dose Mesenchymal Stem Cell therapy in Multiple Myeloma: A Case Report

Case Report | Open Access Volume 8 | Issue 1 |

  • 1. Top IVF USA, Hacienda Heights, CA
  • 2. Loma Linda University School of Medicine, Loma Linda, CA
  • 3. Stem Cell Life Science Corp., New Taipei City, Taiwan
+ Show More - Show Less
Corresponding Authors
Fu Nan Wang, Top IVF USA, Hacienda Heights, CA Stem Cell Life Science Corp, New Taipei City, Taiwan.
Abstract

Multiple myeloma (MM) is a highly malignant cancer characterized by the proliferation and accumulation of monoclonal plasma cells in the bone marrow along with end-organ damage due to the underlying disorder. Despite the remarkable progress in the treatment of MM with the availability of novel agents and hematopoietic cell transplantations (HCTs), an overwhelming majority of patients relapse and the disease is generally considered incurable. Here we report a case of a 57-year old male with relapsed MM previously treated with standard of care therapies including high-dose chemotherapy, radiotherapy, and autologous HCT. Based on our previous success with mesenchymal stem cell (MSC)-based therapy and its favorable safety profile, allogeneic MSC infusions were offered as a treatment option. A daily dose of 5.0 × 108 MSCs was slowly administered intravenously for about one and a half hours to the patient for ten consecutive days. Three months after the treatment, his laboratory results had returned to within normal ranges and MRI showed complete resolution of the lesions. There were no significant adverse effects after administration of MSCs during the course of treatment and follow-up. The patient has since been cancer-free and no longer suffers from osteoporosis, which is usually a life-long complication for patients with MM. This first-in-human study showed that a high cumulative dose of MSCs is a safe and curative treatment for MM.

Cite this article

Wang SG, Hsu NC, Wang SM, Hsu MC, Wang FN (2021) First-In-Human High-Cumulative-Dose Mesenchymal Stem Cell therapy in Multiple Myeloma: A Case Report. J Hematol Transfus 8(1): 1090.

INTRODUCTION

Multiple myeloma (MM) is a hematopoietic malignant disorder characterized by a clonal expansion of terminally differentiated plasma cells in the bone marrow. The plasma cells proliferate in the bone marrow and infiltrate the kidney and other organs can result in extensive skeletal destruction, renal failure, anemia, hypercalcemia and recurrent infections [1,2]. MM accounts for about 1% of all new cancer cases in the United States, and is the second most frequent blood cancer, constituting about 10% of all hematologic malignancies [3]. Various types of treatment exist for MM, including chemotherapy, corticosteroids, immunomodulators, monoclonal antibodies, histone deacetylase inhibitors, proteasome inhibitors, radiation, and hematopoietic cell transplantations (HCTs) which have contributed to a significant improvement in overall survival in the last 15 years [4]. However, despite the remarkable progress in survival, it remains a fatal disease.

Mesenchymal stem cells (MSCs) are a major constituent of the bone marrow microenvironment. They possess the ability to self-renew and differentiate into several lineages, including osteoblasts, chondrocytes, adipocytes, and fibroblasts [5-8]. Accumulating evidence indicates that MSCs in MM are phenotypically and functionally different from normal MSCs, and the aberrant MSCs promote osteolytic lesions, support MM cell growth and drug resistance through direct cell-to-cell contact, cytokine release, and exosome secretion [9-17]. In contrast, aberrant MSCs from MM patients stimulate tumor growth and disease progression. Expanded MSCs isolated from postpartum human placenta effectively suppress MM-induced bone disease and tumor growth in bone by inhibiting osteoclastogenesis and stimulating endogenous osteoblastogenesis [18]. Intrabone or sequential intravenously injected expanded human fetal bonederived MSCs act as bystander cells to inhibit MM-induced bone disease in the mouse model [19]. The pathologic characteristics of MM-related osteolytic lesions and the acceptable safety profile of MSCs support the potential of exogenous healthy MSCbased therapies for this disease [18-22]. This case reports the results obtained from a relapsed MM patient treated with highcumulative-dose allogeneic MSCs.

 

CASE REPORT

A 57-year-old male relapsed MM presented with fatigue, myalgia, anorexia, renal insufficiency, and generalized weakness. Magnetic resonance imaging (MRI) of the spine and extremities revealed a total of eighteen variable-sized, well-defined lesions. Cancer cells had invaded the orbital bone of his right eye causing the eye to spontaneously shed tears. As a result, his oncologist recommended surgical removal of his right eyeball. Laboratory findings were remarkable for a WBC of 3.28 × 103 /μl, platelet count of 116 × 103 /μl and red blood cell distribution width (RDWCV) of 16.0%. Electrophoresis identified a large amount of lambda (27.6 mg/l) and kappa-free light chains (27.6 mg/l). The patient had received high-dose chemotherapy, radiotherapy, and autologous HCT but with limited response. Due to his deteriorating health, and the lack of response to prior treatments, we offered allogeneic MSC infusions as a treatment option based on our previous success with MSC-based therapy and its favorable safety profile. The patient was well-informed regarding the experimental nature of the protocol and provided written informed consent for treatment and data publication.

MSCs from human gingiva were prepared as previously described [23]. A biopsy of gingival connective tissue from a healthy donor was crushed into small pieces and were cultured in αMEM (ThermoFisher Scientific, Grand Island, NY, USA) supplemented with 10% AB serum (Sigma-Aldrich, St Louis, MO, USA). Antibiotics, 100 U/ml penicillin, 100 μg/ml streptomycin, and 0.25 μg/ml Amphotericin B (ThermoFisher) were added to the culture for the first two passages. The medium was replaced three times a week, and adherent cells were allowed to reach 85% confluent before they were sub-cultured with trypsin?EDTA. The resulting cells were harvested and expanded in vitro for 4 weeks.

The cells are prepared by resuspending them in 2 mL of patient’s own serum and injected into a bag of Lactated Ringer IV solution before slowly administered intravenously intravenously over one and a half hours to the patient. The patient received a daily dose of 5.0 × 108 MSCs for ten consecutive days. After each infusion, the patient was closely monitored for the following symptoms: fever, chillness, nausea, vomiting, skin rash, cough, dyspnea, wheezing, chest pain, cyanosis, sputum production, hemoptysis, palpitation, and pain of extremity signs of tumor development. During the entire course of treatment, none of these symptoms were reported. Prior to MSCs treatment, the patient experienced complete hair loss and involuntarily trembling fingers after receiving multiple cycles of chemotherapy and radiotherapy. Two weeks after treatment, his fingers stopped shaking uncontrollably and his scalp hair started to grow back. The patient’s skin hyperpigmentation cleared and his right eye no longer spontaneously shed tears. All laboratory tests returned to within normal ranges and MRI showed no residual cancer three month after the MSC treatment. The patient has since been cancer-free and suffered no symptoms to date. In addition, he no longer suffered from osteoporosis, which is usually a life-long complication for patients with MM.

 

DISCUSSION

The main treatment options for MM are chemotherapy alone or chemotherapy plus HCT. Although allogeneic HCT may be a potentially curative treatment for MM, initial high dose chemotherapy followed by allogeneic HCT cannot commonly be employed due to the fact that the majority of patients are older age and/or have comorbidities which makes them ineligible. Moreover, this regimen is associated with high rates of overall mortality and the probability of cure is very low [24-26].

MSCs from patients with MM possess aberrant genomic,phenotypic, and functional properties [9,13,16,17]. Crosstalk between tumor cells and MSCs in the bone marrow microenvironment has been shown to increase the metastatic potential and promote epithelial-to-mesenchymal transition [27]. It is well-established that abnormalities in MM bone marrow MSCs play a vital role in myeloma cell growth, progression, and relapse [11, 28,29]. Altering the bone marrow microenvironment by administering exogenous MSCs has been shown to suppress the growth of MM, prevent bone loss, and stimulate bone formation [18]. The inhibitory effect of MSCs on tumor growth has been reported in various animal tumor models including breast cancer [30], Kaposi’s sarcoma [31], hepatoma [32] and melanoma [33]. An immunodeficiency SCID-rab MM model showed that exogenous MSCs act as bystander cells to inhibit MM-induced bone disease and tumor growth. Furthermore, systemically injected MSCs are attracted to bone by MM cells and inhibit bone disease [19]. MSCs express Fas-L which induce MM cell apoptosis in vivo, and inhibit the growth and metastasis of MM in vitro and in vivo [34]. Based on these findings, a novel MSCbased cytotherapy may be a promising therapeutic approach for myeloma osteolysis.

Human gingival-derived MSCs are a class of cells with unique self-renewal and multilineage differentiation properties [35]. These cells display stable morphology, maintain normal karyotype and telomerase activity at high passages, and are not tumorigenic [36]. We previously demonstrated that gingival MSCbased cytotherapy was safe and curative for the management of severe psoriasis [23]. In this study, we showed that a significantly more intensive intervention with respect to both the individual MSCs dose and the frequency of dose administration is an effective treatment strategy for MM. This report is the first to show the safety and curative effect of high-cumulative-dose MSCs in MM. The patient has been monitored for four years and has remained cancerfree.

In contrast to the research described above, MSCs have also been implicated in tumor growth, progression, and metastasis [21, 27, 37]. The potentially supportive role of MSCs in tumor growth and metastasis raises concerns about the safety of their use in a clinical setting. MSCs reside in the bone marrow stroma alongside hematopoietic stem cells (HSCs) and play a supportive role for HSCs. Capable of suppressing T-cell activation, human MSCs have previously been used to enhance long-term HSC engraftment in human transplantation [38]. To date, data from human clinical trials performed with allogeneic MSCs have shown mixed therapeutic outcomes; however, no evidence of tumor formation and severe adverse events has been reported in over 1000 patients treated with MSC for a variety of indications.

The treatment of MM is progressing rapidly with advances being made in autologous and allogeneic transplantation and the development of novel anti-MM agents. The results of this first-in-human study revealed that a high cumulative dose of MSCs is a safe and curative treatment for MM, and these findings warrant further clinical exploration toward a new step in stem cell transplantation. Combining standard of care therapies with novel strategies to achieve synergistic responses is a particularly promising approach in MM. Future research should validate the safe/efficacy of combined application of transplantation, novel agents, and cytotherapy for the treatment of MM. The evidence presented in this report supports the notion that MM could be a manageable chronic disease and perhaps a curable disease for some.

REFERENCES

1. Palumbo K and Anderson K. Multiple myeloma. N Engl J Med. 2011; 364: 1046-1060.

2. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78: 21-33.

3. Bergsagel PL and Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005; 23: 6333-6338.

4. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014; 28: 1122-1128.

5. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R. Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284: 143-147

6. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement, Cytotherapy. 2006; 8: 315-317.

7. Bianchi G and Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood; 125: 3049-3058.

8. Reagan MR and Ghobrial IM. Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin Cancer Res. 2012; 18: 342-349.

9. Garderet L, Mazurier C, Chapel A, Ernou I, Boutin L, Holy X. Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk Lymphoma. 2007; 48: 2032-2041.

10.Abe M. Cytokines and myeloma bone disease. Clin Calcium. 2014; 24: 871-878.

11.Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest; 123: 1542-1555.

12.Hideshima T, Mitsiades C, Tonon G, Richardson PG and Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer; 7: 585-598.

13.Garayoa M, Garcia JL, Santamaria C, Garcia-Gomez A, Blanco JF. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia. 2009; 23: 1515-1527.

14.Garcia-Gomez A, Sanchez-Guijo F, Del Canizo MC, San Miguel JF and Garayoa M. Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics. World J Stem Cells. 2014; 6: 322-343.

 15.Garcia-Gomez A, De Las Rivas J, Ocio EM, Diaz-Rodriguez E, Montero JC. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease. Oncotarget; 5: 8284-8305.

16.Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia. 2007; 21: 1079-1088.

17.Wallace SR, Oken MM, Lunetta KL, Panoskaltsis-Mortari A and Masellis AM. Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer; 91: 1219-1230.

18.Ling X Li W, Pennisi A, Wang Y, Khan S, Heidaran M. Human placentaderived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone. Stem Cells; 29: 263-273.

19.Ling X Li W, S. Khan and Yaccoby S. Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth. J Bone Miner Res. 27: 1635-1648.

20.Gasparetto C. Stem cell transplantation for multiple myeloma. Cancer Control. 2004; 11: 119-129.

21.Klopp AH, Gupta A, Spaeth E, Andreeff M and Marini F. Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth?. Stem Cells. 2011; 29: 11-19.

22.Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ et al. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells. 2006; 24: 986-991.

23.Wang SG, Hsu NC, Wang SM. and Wang FN. Successful Treatment of Plaque Psoriasis with Allogeneic Gingival Mesenchymal Stem Cells: A Case Study. Case Rep Dermatol Med. 2020; 4617520.

24.Dhakal B, Vesole DH and Hari PN. Allogeneic stem cell transplantation for multiple myeloma: is there a future? Bone Marrow Transplant. 2016; 51: 492- 500.

25.Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM. Standard chemotherapy compared with highdose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006; 24: 929-936.

26.Bjorkstrand BB, Ljungman P, Svensson H, Hermans J, Alegre A. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective casematched study from the European Group for Blood and Marrow Transplantation. Blood. 1996; 88: 4711-4718.

27.Ridge SM, Sullivan FJ and Glynn SA. Mesenchymal stem cells: key players in cancer progression. Mol Cancer. 2017; 16: 31.

28.Dabbah M, Attar-Schneider O, Zismanov V, Tartakover Matalon S, Lishner M. Multiple myeloma cells promote migration of bone marrow mesenchymal stem cells by altering their translation initiation. J Leukoc Biol. 2016; 100: 761-770.

29.Andre T, Meuleman N, Stamatopoulos B, De Bruyn C, Pieters K. Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells. PLoS One. 2013; 8: e59756, 2013.

30.Sun B, Roh KH, Park JR, Lee SR, Park SB. Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model. Cytotherapy. 2009. 11: 289-298.

31.Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J Exp Med. 2006; 203: 1235-1247.

32.Qiao L, Z. Zhao Xu T, Zhao Z, Shi M, Zhao RC. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res. 2008; 18: 500-507.

33.Otsu K, Das S, Houser SD, Quadri SK, Bhattacharya S. Concentrationdependent inhibition of angiogenesis by mesenchymal stem cells. Blood. 2009; 113: 4197-4205.

34.Atsuta I, Liu S, Miura Y, Akiyama K, Chen C. Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway. Stem Cell Res Ther. 2013; 4: 111.

35.Grawish ME. Gingival-derived mesenchymal stem cells: An endless resource for regenerative dentistry. World J Stem Cells. 2018; 10: 116-118.

36.Tomar GB, Srivastava RK, Gupta N, Barhanpurkar AP, Pote ST. Human gingiva-derived mesenchymal stem cells are superior to bone marrowderived mesenchymal stem cells for cell therapy in regenerative medicine. Biochem Biophys Res Commun. 2010; 393: 377-383.

37.Xu S, De Veirman K, De Becker A, Vanderkerken K and Van Riet I. Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target? Leukemia. 2018; 32: 1500-1514.

38.Maitra B, Szekely E, Gjini K, Laughlin MJ, Dennis J. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant. 2004; 33: 597- 604

Wang SG, Hsu NC, Wang SM, Hsu MC, Wang FN (2021) First-In-Human High-Cumulative-Dose Mesenchymal Stem Cell therapy in Multiple Myeloma: A Case Report. J Hematol Transfus 8(1): 1090

Received : 29 Apr 2021
Accepted : 13 May 2021
Published : 15 May 2021
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
TEST Journal of Dentistry
ISSN : 1234-5678
Launched : 2014
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X